IPP Bureau
Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
By IPP Bureau - February 17, 2022
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Asahi Kasei to build new filter assembly plant in Japan
By IPP Bureau - February 17, 2022
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
By IPP Bureau - February 17, 2022
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
USFDA approves Lupin’s Supplemental New Drug Application for Solosec
By IPP Bureau - February 17, 2022
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Centauri Therapeutics closes £ 24 million Series A investment round
By IPP Bureau - February 17, 2022
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
By IPP Bureau - February 17, 2022
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Nirsevimab EMA regulatory submission accepted under accelerated assessment
By IPP Bureau - February 17, 2022
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Moderna announces expansion in key Asian markets
By IPP Bureau - February 16, 2022
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine
By IPP Bureau - February 16, 2022
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
Rapid Medical receives USFDA designation for Comaneci
By IPP Bureau - February 16, 2022
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Clean Science and Technology to invest Rs. 300 - 500 Cr on expansion
By IPP Bureau - February 16, 2022
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Lantern Pharma collaborates with GCCRI for pediatric cancer
By IPP Bureau - February 16, 2022
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
GOQii raises US $ 50 million Series C funding
By IPP Bureau - February 16, 2022
Funding to grow the insurance and digital therapeutics vertical in India
Proactive For Her raises US $ 5.5 million in Series A Round
By IPP Bureau - February 16, 2022
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Ayu Health acquires SwasthyaSewak Hospitals in Jaipur
By IPP Bureau - February 16, 2022
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
